直接抗病毒药物治疗慢性丙型肝炎的作用机制

近年来随着直接抗病毒药物（DAAs）在全球的研发上市,慢性丙型肝炎的治疗方案不断演化,DAAs在我国也即将上市。DAAs主要作用于HCV的非结构蛋白,抑制HCV RNA的复制。介绍了各类DAAs的作用靶位、作用机制、耐药特性以及在中国的研发现状和临床Ⅲ期试验结果,旨在为慢性丙型肝炎DAAs联合其他抗病毒治疗方案提供临床参考。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 32; no. 9; pp. 1699 - 1705
Main Author 温晓玉 牛俊奇
Format Journal Article
LanguageChinese
Published 吉林大学白求恩第一医院肝胆胰内科,长春,130021 2016
Subjects
抗病毒药
治疗
肝炎,丙型,慢性
治疗
抗病毒药
肝炎,丙型,慢性
antiviral agents
hepatitis C,chronic
therapy
Online AccessGet full text
ISSN1001-5256
DOI10.3969/j.issn.1001-5256.2016.09.013

Cover

More Information
Summary:近年来随着直接抗病毒药物（DAAs）在全球的研发上市,慢性丙型肝炎的治疗方案不断演化,DAAs在我国也即将上市。DAAs主要作用于HCV的非结构蛋白,抑制HCV RNA的复制。介绍了各类DAAs的作用靶位、作用机制、耐药特性以及在中国的研发现状和临床Ⅲ期试验结果,旨在为慢性丙型肝炎DAAs联合其他抗病毒治疗方案提供临床参考。
Bibliography:hepatitis C; chronic; antiviral agents; therapy
With the development and launch of direct- acting antiviral agents（ DAAs） in the world in recent years,therapeutic regimens for chronic hepatitis C are constantly evolving. DAAs will also be launched in China in the near future. DAAs mainly target at the non-structural proteins of HCV and can inhibit HCV RNA replication. This article introduces the targets,mechanism of action,and resistance characteristics of different DAAs,as well as their current research and development in China and the results of phase Ⅲ clinical studies,in order to provide a reference for combined therapeutic strategies with DAAs in the treatment for chronic hepatitis C.
WEN Xiaoyu, NIU Junqi. （Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China）
22-1108/R
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2016.09.013